Amgen – Five Hours Before The Market Open, Amgen Is Down By 1%

NASDAQ Composite opens in less than five hours and Amgen’s pre-market value is already 1.66% down.

The last session, NASDAQ Composite ended with Amgen sliding 1.32% to $247.75. NASDAQ Composite slid 0% to $13,337.16, following last session’s upward trend on what was a somewhat positive trend trading session.

Amgen’s last close was $247.75, 11.68% below its 52-week high of $276.69.

Amgen’s Sales

Amgen’s sales growth is 6.3% for the ongoing quarter and 3.1% for the next. The company’s growth estimates for the present quarter and the next is a negative 6.6% and a negative 1%, respectively.

Amgen’s Revenue

Year-on-year quarterly revenue growth grew by 12%, now sitting on 24.99B for the twelve trailing months.

Amgen’s Stock Yearly Top and Bottom Value

Amgen’s stock is valued at $247.75 at 04:46 EST, way under its 52-week high of $276.69 and way above its 52-week low of $177.05.

Amgen’s Moving Average

Amgen’s worth is higher than its 50-day moving average of $235.38 and above its 200-day moving average of $238.90.

Volatility

Amgen’s last day, last week, and last month’s average volatility was a negative 1.34%, a negative 0.35%, and a positive 0.49%, respectively.

Amgen’s last day, last week, and last month’s high and low average amplitude percentage was 13.65%, 4.58%, and 2.70%, respectively.

Previous days news about Amgen

Amgen drug shrunk 37% of lung cancer tumors in study. According to Bloomberg Quint on Thursday, 28 January, “An Amgen Inc. lung cancer drug shrunk tumors in 37% of patients for whom chemotherapy and other drugs hadn’t worked, and prevented malignancies from progressing for a median of 6.8 months, the company said on Thursday.”, “That prompted Amgen to consider who are the best patients to treat and whether the drug works better on its own or in combination, Friberg said.”